Replimune Group, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of Replimune Group, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Biotechnology
Multiples of its companies with a market value at most 60 days old, times Replimune Group, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Replimune Group, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to book | 3.1× / 4.5× / 12.9× | 9.9× | book equity $166 M | $508 M to $2.1 B | 69 |
Against its own history
Replimune Group, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
Price to book
9.9×Now above its median of 2.0×, in the top quarter of its range; range 0.8× to 10.5× over 26 months.
As of Oct 30, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Mar 31, 2026 | — | $-314 M | $-280 M | $4 M | $-285 M | $-126 M | SEC annual report (10-K, 20-F) |
| FY2024to Mar 31, 2025 | — | $-247 M | $-192 M | $7 M | $-199 M | $-65 M | SEC annual report (10-K, 20-F) |
| FY2023to Mar 31, 2024 | — | $-216 M | $-185 M | $6 M | $-191 M | $-30 M | SEC annual report (10-K, 20-F) |
| FY2022to Mar 31, 2023 | — | $-174 M | $-128 M | $2 M | $-130 M | $-118 M | SEC annual report (10-K, 20-F) |
| FY2021to Mar 31, 2022 | — | $-118 M | $-82 M | $2 M | $-85 M | $-106 M | SEC annual report (10-K, 20-F) |
| FY2020to Mar 31, 2021 | — | $-81 M | $-61 M | $2 M | $-64 M | — | SEC annual report (10-K, 20-F) |